

# Synthesis of bhimamycin B based on oxidative rearrangement of 4-acetylnaphtho[1,2-*b*]furan-5-ol to naphtho[2,3-*c*]furan-4,9-dione

Hidemitsu Uno,\* Seiya Murakami, Akiko Fujimoto and Youtarou Yamaoka

Division of Synthesis and Analysis, Department of Molecular Science, Integrated Center for Sciences, 2-5 Bunkyo-cho, Matsuyama 790-8577, Japan

Received 3 March 2005; revised 9 April 2005; accepted 11 April 2005


**Abstract**—The first total synthesis of bhimamycin B, a novel member of naphtho[2,3-*c*]furan quinone antibiotics, was achieved by oxidative skeletal rearrangement of 4-acetylnaphtho[1,2-*b*]furan-5-ol. © 2005 Elsevier Ltd. All rights reserved.

A naphtho[*c*]furan skeleton, furan fused with naphthalene at  $\beta,\beta$ -positions, is not common in a various kind of naturally occurring furanonaphthoquinones and a few compounds have been reported so far.<sup>1</sup> Recently, Fotso et al. isolated an interesting new member of antibacterial naphtho[1,2-*c*]furan quinones, namely bhimamycins, from *Streptomyces* sp. GW32/698 together with dihydroxyanthraquinones such as chrysophanol and aloesaponarin.<sup>2</sup> We already reported our successful approach to the dihydroxyanthraquinones based on biomimetic intramolecular condensation of octaketide-mimicking compounds.<sup>3</sup> If our route would be close to the natural metabolic pathways to such dihydroanthraquinones, bhimamycins could be also synthesized from our key intermediates by a proper choice of reagents. This is proven by using naphtho[1,2-*b*]furan **2**<sup>3</sup> as the key compound. In this communication, we would like to show the first synthesis of bhimamycin B based

on the oxidative skeletal rearrangement of naphtho[1,2-*b*]furan to naphtho[2,3-*c*]furan.

Retro-synthetic analysis of bhimamycin B is shown in Scheme 1. The furan ring of bhimamycin B is cleaved between C1 and oxygen to give hydrojuglone derivative **1** with acetyl and pyruvic units, which may be in turn obtained by oxidative cleavage of naphtho[1,2-*b*]furan **2**.

Preparation of naphtho[1,2-*b*]furan **2** was achieved by the Lewis acid-promoted reaction of acetyljuglone derivative **3**<sup>4</sup> with 2-(trimethylsiloxy)propene followed by treatment with  $\text{Ac}_2\text{O}$ /pyridine and saponification with aq-NaOH (Scheme 2). First, we tried to introduce a bromine atom at the 3-position of **2**. Treatment of **2** with NBS in dichloromethane, however, gave a 9-bromo derivative of **2** in quantitative yield. This result is easily rationalized by HOMO coefficients of the unsubstituted



**Scheme 1.** Retro-synthesis of bhimamycin B.

**Keywords:** Bhimamycin B; Iodosobenzene diacetate; Naphtho[2,3-*c*]furan.


\* Corresponding author. Tel.: +81 89 927 9660; fax: +81 89 927 9670; e-mail: uno@dpc.ehime-u.ac.jp

positions of **2** calculated by MOPAC.<sup>5</sup> The calculation also revealed that the C3 carbon had the largest negative electron density (0.325) among the unsubstituted carbon atoms. Therefore, we examined the oxidation reaction of **2** under various conditions<sup>6</sup> and the results are summarized in Table 1.

Treatment of **2** with 2.2-molar equivalents of ceric(IV) ammonium nitrate (CAN)<sup>7</sup> gave single product (run 1), which was proven to be 5-*O*-methylbhimamycin B (**4**) by spectroscopic data<sup>†</sup> and finally by X-ray crystallographic analysis (Fig. 1).<sup>8</sup> However, the yield was quite low (18%) due to resinous material formation. This could not be improved by change of the equivalent of CAN. Oxidation of **2** with a 2.0-molar ratio of Pb(OAc)<sub>4</sub><sup>8</sup> gave a mixture of two compounds (run 2), which were assigned to be orthoquinone **5** (10%) and acetoxylated compound **6** (33%) by spectroscopic<sup>†</sup> and X-ray data (Fig. 1).<sup>8</sup> These yields were both improved by increasing molar ratio of Pb(OAc)<sub>4</sub> (run 3). The acetoxylated compound **6** was rather unstable and partially decomposed during the recrystallization from ethanol. From the mother liquid, presence of orthoquinone **5** was detected. Oxidation of PhI(OAc)<sub>2</sub><sup>9</sup> gave completely different results (runs 4–7). Treatment of PhI(OAc)<sub>2</sub> (2.0-molar ratio) gave a mixture of **4** (14%) and **7** (17%) as well as recovery of the starting material. The best result was obtained by using a 6.0-molar ratio of PhI(OAc)<sub>2</sub> and 5-*O*-methylbhimamycin B (**4**) was

<sup>†</sup> Spectroscopic data for **4**:  $\delta_H$  (CDCl<sub>3</sub>) 7.96 (1H, d,  $J$  = 7.6 Hz), 7.73 (1H, dd,  $J$  = 8.6 and 7.6 Hz), 7.36 (1H, d,  $J$  = 8.6 Hz), 4.05 (3H, s), 2.84 (3H, s) and 2.83 (3H, s);  $\delta_C$  (CDCl<sub>3</sub>) 187.2, 180.0, 179.1, 161.4, 160.8, 147.8, 138.2, 135.1, 123.0, 122.3, 120.6, 119.9, 118.2, 56.6, 29.2 and 14.2;  $\nu_{max}$  (KBr) 1682 and 1656 cm<sup>-1</sup>. Compound **5**:  $\delta_H$  (CDCl<sub>3</sub>) 7.56 (1H, d,  $J$  = 7.6 Hz), 7.30 (1H, dd,  $J$  = 8.6 and 7.6 Hz), 7.02 (1H, d,  $J$  = 8.6 Hz), 6.43 (1H, s), 3.99 (3H, s), 22.41 (3H, s);  $\delta_C$  (CDCl<sub>3</sub>) 179.5, 174.2, 162.6, 159.2, 155.7, 136.5, 130.3, 122.1, 115.2, 114.5, 114.2, 104.3, 56.24 and 13.6;  $\nu_{max}$  (KBr) 1674 and 1562 cm<sup>-1</sup>. Compound **6**:  $\delta_H$  (CDCl<sub>3</sub>) 7.54 (1H, t,  $J$  = 8.1 Hz), 7.25 (1H, d,  $J$  = 8.1 Hz), 6.85 (1H, d,  $J$  = 8.1 Hz), 5.99 (1H, s), 3.92 (3H, s), 2.36 (3H, s) 2.30 (3H, s) and 2.18 (3H, s);  $\delta_C$  (CDCl<sub>3</sub>) 198.7, 198.3, 168.6, 161.3, 154.8, 147.1, 136.3, 132.6, 120.0, 114.5, 112.8, 111.1, 105.2, 56.1, 25.9, 20.9 and 14.0;  $\nu_{max}$  (KBr) 1755, 1697, 1227 and 1007 cm<sup>-1</sup>. Compound **7**:  $\delta_H$  (CDCl<sub>3</sub>) 14.05 (1H, s changeable with D<sub>2</sub>O), 7.83 (1H, d,  $J$  = 8.1 Hz), 7.65 (1H, t,  $J$  = 8.1 Hz), 7.23 (1H, d,  $J$  = 8.1 Hz), 4.07 (3H, s), 3.89 (1H, s, changeable with D<sub>2</sub>O), 2.72 (3H, s) and 1.73 (3H, s);  $\delta_C$  (CDCl<sub>3</sub>) 202.6, 196.7, 165.4, 158.9, 158.7, 131.0, 126.2, 120.1, 115.5, 112.7, 198.7, 103.7, 56.5, 31.3, 22.1 and one carbon is not found due to overlap;  $\delta_C$  (DMSO-*d*<sub>6</sub>) 200.5, 197.1, 163.2, 157.3, 147.8, 129.7, 123.6, 119.1, 114.8, 114.2, 112.0, 109.5, 105.0, 56.7, 31.5 and 22.0;  $\nu_{max}$  (KBr) 3425 and 1712 cm<sup>-1</sup>.

<sup>‡</sup> Crystallographical data for **4**: C<sub>16</sub>H<sub>12</sub>O<sub>5</sub>; FW = 284.26, orange prisms, 0.15 × 0.10 × 0.10 mm, monoclinic, *P*-1 (#2), *Z* = 2 in a cell of dimensions *a* = 7.716(2) Å, *b* = 9.803(2) Å, *c* = 10.166(2) Å,  $\alpha$  = 109.43(2) $^\circ$ ,  $\beta$  = 110.61(2) $^\circ$ ,  $\gamma$  = 98.98(3) $^\circ$  *V* = 645.4(3) Å<sup>3</sup>, *D*<sub>calcd</sub> = 1.463 g cm<sup>-3</sup>, Mo K $\alpha$ , *F*(000) = 296.0, 2857 unique reflections, 1893 with  $F^2 > 2\sigma(F^2)$ . The final *R*<sub>1</sub> = 0.079, *R*<sub>w</sub>(*all*) = 0.168, goodness-of-fit = 1.16 for 191 parameters refined on *F*<sup>2</sup>. CCDC 256976. Compound **5**: C<sub>14</sub>H<sub>10</sub>O<sub>4</sub>; FW = 242.23, red rods, 0.60 × 0.15 × 0.15 mm, monoclinic, *P*<sub>2</sub><sub>1</sub>/*n* (#14), *Z* = 4 in a cell of dimensions *a* = 7.620(4) Å, *b* = 11.236(4) Å, *c* = 13.321(4) Å,  $\beta$  = 91.13(4) $^\circ$ , *V* = 1140.2(8) Å<sup>3</sup>, *D*<sub>calcd</sub> = 1.411 g cm<sup>-3</sup>, Mo K $\alpha$ , *F*(000) = 504.0, 2611 unique reflections, 1338 with  $F^2 > 2\sigma(F^2)$ . The final *R*<sub>1</sub> = 0.064, *R*<sub>w</sub>(*all*) = 0.188, goodness-of-fit = 1.01 for 164 parameters refined on *F*<sup>2</sup>. CCDC 256977.




**Scheme 2.** Reagents, conditions and yields: (i) 2-(trimethylsilyloxy)-propene, SnCl<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C; Ac<sub>2</sub>O, pyridine, rt; 1.0 M NaOH, MeOH/THF; 65%. (ii) See in Table 1.

obtained in 57% yield. As treatment of **7** with acetic acid did not give **4**, compound **7** is a shunt product. Oxidations using other oxidants such as OsO<sub>4</sub> and Dess–Martin periodinane resulted in the formation of orthoquinone **5** in low yields (3% and 8%, respectively). Oxidation of 3-acetyl-2-(2-oxopropyl)-5-methoxy-1,4-naphthoquinone (**8**) with PhI(OAc)<sub>2</sub> also gave 5-*O*-methylbhimamycin B (**4**), but the yield was low (20%). Demethylation of 5-*O*-methylbhimamycin B (**4**) with AlCl<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> at room temperature gave bhimamycin B in 56% yield. Spectroscopic and physical data of the synthetic bhimamycin B is completely identical with the natural ones.

At this moment, it is difficult to figure out the oxidation mechanism. Taking the characteristic reaction feature of Pb(OAc)<sub>4</sub> and PhI(OAc)<sub>2</sub> into account,<sup>6,10</sup> however, the possible reaction mechanism is shown in Scheme 3. First, ligand exchange between the naphthoxyl and acetoxy groups would occur in both reagents. In the case of Pb(OAc)<sub>4</sub>, the intermediate **9** [R-X = (AcO)<sub>2</sub>Pb] would decompose via radical process<sup>6</sup> to transfer one acetoxy group at the *ortho* position (C4) and the observed compound **6** was obtained. Then, hydrolysis and further oxidative deacetylation would give the orthoquinone **5**. On the other hand, the ionic process would be favoured in the case of PhI(OAc)<sub>2</sub>.<sup>10</sup> Therefore, the less hindered C9b would be attacked by an acetoxy anion to afford **10**. Hydrolysis of **10** would give **11**, which then decomposed to give **8**. The acetonynaphthoquinone **8** would be acetoxylated and then hydrolyzed to give **13**. The

**Table 1.** Oxidation of naphtho[1,2-*b*]furanol **2**

Run	Reagent (mol. ratio)	Solvent	Product/% <sup>a</sup>			
			4	5	6	7
1	CAN (2.2)	aq-MeCN	18	—	—	—
2	Pb(OAc) <sub>4</sub> (2.0)	EtOAc	—	10	33	—
3	Pb(OAc) <sub>4</sub> (4.0)	EtOAc	—	16	40	—
4	PhI(OAc) <sub>2</sub> (2.0)	MeCN	14	—	—	17
5	PhI(OAc) <sub>2</sub> (4.0)	MeCN	27	—	—	—
6	PhI(OAc) <sub>2</sub> (6.0)	MeCN	57	—	—	—
7	PhI(OAc) <sub>2</sub> (8.0)	MeCN	38	—	—	—

<sup>a</sup> Isolated yield.**Figure 1.** ORTEP drawing of **4** (left) and **5** (right) with 50% probability.


quinone **13** would directly undergo the dehydrative cyclization to give **4** (Route c), or enolized to the more stable form **14**, which would exist as a tautomeric mixture of **14a** and **14b**. Cyclization from tautomer

**14b** followed by dehydration would also give *5*-*O*-methylibhimamycin B (**4**), while cyclization from tautomer **14a** would afford **7**. From this scheme, the lower yield of **4** from **8** and no formation of compound **7** by increase of PhI(OAc)<sub>2</sub> could not be explained. Further mechanistic investigation is required.

In conclusion, we succeeded in the first synthesis of bhimamycin B based on the novel oxidative ring system transformation of naphtho[1,2-*b*]furan to naphtho[2,3-*c*]furan.

### Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.tetlet.2005.04.037](https://doi.org/10.1016/j.tetlet.2005.04.037).

**Scheme 3.** Tentative reaction mechanism.

### References and notes

1. Thomson, R. H. *Naturally Occurring Quinones IV*; Blackie Academic & Professional: London, 1997.
2. Fotso, S.; Maskey, R. P.; Grün-Wollny, I.; Schulz, K.-P.; Munk, M.; Laatsch, H. *J. Antibiot.* **2003**, *56*, 931.
3. Uno, H.; Masumoto, A.; Honda, E.; Nagamachi, Y.; Yamaoka, Y.; Ono, N. *J. Chem. Soc., Perkin Trans. 1* **2001**, 3189.
4. Uno, H. *J. Org. Chem.* **1986**, *51*, 350.
5. CambridgeSoft, MOPAC pro ver. 7.0.0.212.
6. Review for oxidation of phenols, see: Naruta, Y.; Maruyama, K. In *The Chemistry of Quinonoid Compounds*; Patai, S., Rappoport, Z., Eds.; John Wiley & Sons: New York, 1988; Vol. II; Akai, S.; Kita, Y. *Org. Prep. Proc.* **1998**, *30*, 603.
7. Jacob, P.; Callery, P. S.; Shulgin, A. T.; Castagnoli, N. *J. Org. Chem.* **1976**, *41*, 3627.
8. Begley, M. J.; Gill, G. B.; Pattenden, G.; Stapleton, A. *J. Chem. Soc., Perkin Trans. 1* **1988**, 1677.
9. Tamura, Y.; Yakura, T.; Tohma, H.; Kikuchi, K.; Kita, Y. *Synthesis* **1989**, 126.
10. Varvoglis, A. *Chem. Soc. Rev.* **1980**, 377.